Urticaria Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Jan 2024 Pages: 167 SKU: IRTNTR73292

Urticaria Drugs Market 2024-2028

The Urticaria Drugs Market size is forecast to increase by USD 1.66 billion, at a CAGR of 11.64% between 2023 and 2028. 

There has been an increasing approval of new drugs for urticaria across the world. In addition, urticaria has a strong pipeline, considering the early and late-stage pipeline candidates. Moreover, most drugs are anti-allergens that have a symptomatic management approach. In addition, few promising molecules in the pipeline have disease-modifying activities for chronic spontaneous urticaria, acute urticaria, angioedema, and others. Furthermore, major companies such as Novartis AG, Amneal Pharmaceuticals Inc., F. Hoffmann La Roche Ltd., and Viatris Inc. have a strong pipeline in their portfolios for urticaria indication. Hence, such factors are positively impacting the market.

Technavio has segmented the market into Application, Type, and Geography

  • The application segment is classified into acute urticaria and chronic urticaria 
  • The type segment is classified into antihistamines, anti-inflammatory agents, sulfones, and biologics
  • The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Urticaria Drugs Market During the Forecast Period?

To learn more about this report, Download Report Sample

Urticaria Drugs Market Segmentation by Application, Type and Geography Analysis

Application Analysis 

Acute urticaria

The acute urticaria segment is estimated to witness significant growth during the forecast period. The growth of this segment is fuelled by the fact that acute urticaria is more common than chronic since it mostly occurs as a result of associated allergies or diseases associated with food allergies, post-viral illnesses, etc. In addition, they last less than six weeks and can generally be managed by antihistamines. Furthermore, due to their higher incidence rates than chronic urticaria, they have a higher market share.

Get a glance at the market contribution of various segments Download PDF Sample

The acute urticaria segment was the largest segment and was valued at USD 1.31 billion in 2018. Moreover, the acute urticaria segment of the global urticaria drugs market is expected to show accelerating growth in the forecast period since the incidence of acute urticaria is increasing owing to the increased prevalence of allergic diseases worldwide. In addition, the acute urticaria segment is expected to show an accelerating year-over-year growth with the increasing approval of drugs for acute urticaria. Furthermore, many pharmaceutical companies are performing extensive research in the acute urticaria area and planning to launch their products. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Type Analysis 

Antihistamines

The first-line drug therapy used for the treatment of urticaria comprises sedative antihistamines and non-sedative antihistamines. In addition, the second-line drug therapy includes doxepin and leukotriene inhibitors. Furthermore, the third-line drug therapy includes cyclosporine and colchicine.  Moreover, there is no need for extensive laboratory testing for most patients with antihistamine-responsive chronic urticaria. Hence, first-line antihistamine therapy is practically effective for treating chronic urticaria patients.  Furthermore, the antihistamines used in treating chronic urticaria showed a 44%-90% response rate in various studies. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Anti-inflammatory agents

The global urticaria drugs market comprises various segments, and the anti-inflammatory agents segment is a crucial market segment. In addition, urticaria, commonly known as hives, is an allergic skin condition characterized by itchy, raised welts that appear on the skin. Moreover, anti-inflammatory agents play a significant role in the management and treatment of urticaria. Furthermore, these agents work by reducing inflammation, which helps alleviate the symptoms associated with urticaria, including itching, redness, and swelling. In addition, anti-inflammatory agents function by targeting the underlying inflammatory processes that trigger the release of histamines in the body, causing the allergic reaction. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Factors such as the increasing incidence and the unmet demand for safe and effective urticaria drugs are expected to fuel the market growth in North America. In addition, The market is expected to register accelerating but moderate growth momentum due to research activities of companies in the US, such as Sorrento Therapeutics, which are developing biosimilars for urticaria. Moreover, the US is the major revenue generator in North America, followed by Brazil and Canada. The high prevalence of acute urticaria along with chronic urticaria is the key factor for the high market share of the US. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Key Urticaria Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Allakos Inc: The company offers urticaria drugs that minimizes the release of mediators throughout the allergic inflammatory cascade.

  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Meiji Holdings Co. Ltd.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • TerSera Therapeutics LLC
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Urticaria Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Urticaria Drugs Market Drivers

One of the key factors driving the urticaria drugs market growth is the increasing prevalence of urticaria. Urticaria is a vastly prevalent disorder leading to high medical consultations globally. In addition, there is an increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, autoreactivity, and alcohol consumption. 

Moreover, another factor is the increasing incidence of allergic disorders and infections, which are major risk factors for the incidence of urticaria globally. In addition, these patients are highly immunocompromised, which results in the release of mast cells and histamines, which result in hives. Furthermore, hives affect around 20 percent of people at some time in their life. Hence, such factors are driving the market growth during the forecast period.

Significant Urticaria Drugs Market Trends

A key factor shaping the urticaria drugs market growth is the increasing research funding for urticaria. Despite the presence of different approved therapies for the treatment of urticaria, the global urticaria drug market still has a significant unmet need due to the increasing prevalence of the indication and the lack of highly effective treatment options.  In addition, the unmet need is also due to the unclear pathogenesis of the condition, which makes it difficult for the vendors to find a potential cure.

Moreover, to overcome this challenge, various companies and research institutions are conducting studies to develop novel therapeutics for the treatment of urticaria. In addition, increasing research funding is expected to attract small and mid-sized vendors and researchers to develop novel potential treatments and cures for the treatment of urticaria that is caused by various indications. Hence, such factors are driving the market growth during the forecast period.

Major Urticaria Drugs Market Challenges

The social stigma associated with urticaria is one of the key challenges hindering the urticaria drugs market growth. Due to the social stigma associated with the urticaria condition, access to healthcare systems and the rate of hospitalization may also decrease. In addition, the level of stigmatization may also change based on the geography of residence. Furthermore, certain countries have lesser awareness of dermatological conditions, and patients find fewer employment opportunities leading to economic challenges.

Moreover, dealing with the social stigma may lead to mood disorders like anxiety and depression. In addition, perceived stigma by the patient may also lead to stress and may negatively impact the quality of life of the patient. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Urticaria Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Urticaria Drugs Market Customer Landscape

Segment Overview

The urticaria drugs market report forecasts market growth by revenue at global, regional & country levels and provides a market growth analysis of the latest market trends and analysis and growth opportunities from 2018 to 2028. 

  • Application Outlook
    • Acute urticaria
    • Chronic urticaria
  • Type Outlook
    • Antihistamines
    • Anti-inflammatory agents
    • Sulfones
    • Biologics
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Urticaria Drugs Market Scope

Report Coverage

Details

Page number

167

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 11.64%

Market Growth 2024-2028

USD 1.66 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

10.38

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Urticaria Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the urticaria drugs market between 2023 and 2028
  • Precise estimation of the urticaria drugs market size and its contribution to the market in focus on the parent market
  • Detailed market research and growth analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate market forecast about upcoming market growth and trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough market growth and forecasting of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report of factors that will challenge the growth of urticaria drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global urticaria drugs market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global urticaria drugs market 2018 - 2022 ($ billion)
    • 4.2 Application Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
    • 4.3 Type Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Acute urticaria - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Acute urticaria - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Acute urticaria - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Acute urticaria - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Acute urticaria - Year-over-year growth 2023-2028 (%)
    • 6.4 Chronic urticaria - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Chronic urticaria - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Chronic urticaria - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Chronic urticaria - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Chronic urticaria - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Application
      • Exhibit 42: Market opportunity by Application ($ billion)
      • Exhibit 43: Data Table on Market opportunity by Application ($ billion)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 44: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on Type - Market share 2023-2028 (%)
    • 7.2 Comparison by Type
      • Exhibit 46: Chart on Comparison by Type
      • Exhibit 47: Data Table on Comparison by Type
    • 7.3 Antihistamines - Market size and forecast 2023-2028
      • Exhibit 48: Chart on Antihistamines - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 49: Data Table on Antihistamines - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Chart on Antihistamines - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on Antihistamines - Year-over-year growth 2023-2028 (%)
    • 7.4 Anti-inflammatory agents - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Anti-inflammatory agents - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Anti-inflammatory agents - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Anti-inflammatory agents - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Anti-inflammatory agents - Year-over-year growth 2023-2028 (%)
    • 7.5 Sulfones - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Sulfones - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Sulfones - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Sulfones - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Sulfones - Year-over-year growth 2023-2028 (%)
    • 7.6 Biologics - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Biologics - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Type
      • Exhibit 64: Market opportunity by Type ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Type ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 China - Market size and forecast 2023-2028
      • Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.11 Canada - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 Allakos Inc.
              • Exhibit 115: Allakos Inc. - Overview
              • Exhibit 116: Allakos Inc. - Product / Service
              • Exhibit 117: Allakos Inc. - Key offerings
            • 12.4 Amneal Pharmaceuticals Inc.
              • Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus
            • 12.5 Aurobindo Pharma Ltd.
              • Exhibit 123: Aurobindo Pharma Ltd. - Overview
              • Exhibit 124: Aurobindo Pharma Ltd. - Product / Service
              • Exhibit 125: Aurobindo Pharma Ltd. - Key offerings
            • 12.6 Bayer AG
              • Exhibit 126: Bayer AG - Overview
              • Exhibit 127: Bayer AG - Business segments
              • Exhibit 128: Bayer AG - Key news
              • Exhibit 129: Bayer AG - Key offerings
              • Exhibit 130: Bayer AG - Segment focus
            • 12.7 F. Hoffmann La Roche Ltd.
              • Exhibit 131: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 132: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 133: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 134: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 135: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.8 GlaxoSmithKline Plc
              • Exhibit 136: GlaxoSmithKline Plc - Overview
              • Exhibit 137: GlaxoSmithKline Plc - Business segments
              • Exhibit 138: GlaxoSmithKline Plc - Key news
              • Exhibit 139: GlaxoSmithKline Plc - Key offerings
              • Exhibit 140: GlaxoSmithKline Plc - Segment focus
            • 12.9 Johnson and Johnson
              • Exhibit 141: Johnson and Johnson - Overview
              • Exhibit 142: Johnson and Johnson - Business segments
              • Exhibit 143: Johnson and Johnson - Key news
              • Exhibit 144: Johnson and Johnson - Key offerings
              • Exhibit 145: Johnson and Johnson - Segment focus
            • 12.10 Meiji Holdings Co. Ltd.
              • Exhibit 146: Meiji Holdings Co. Ltd. - Overview
              • Exhibit 147: Meiji Holdings Co. Ltd. - Business segments
              • Exhibit 148: Meiji Holdings Co. Ltd. - Key news
              • Exhibit 149: Meiji Holdings Co. Ltd. - Key offerings
              • Exhibit 150: Meiji Holdings Co. Ltd. - Segment focus
            • 12.11 Novartis AG
              • Exhibit 151: Novartis AG - Overview
              • Exhibit 152: Novartis AG - Business segments
              • Exhibit 153: Novartis AG - Key offerings
              • Exhibit 154: Novartis AG - Segment focus
            • 12.12 Otsuka Holdings Co. Ltd.
              • Exhibit 155: Otsuka Holdings Co. Ltd. - Overview
              • Exhibit 156: Otsuka Holdings Co. Ltd. - Business segments
              • Exhibit 157: Otsuka Holdings Co. Ltd. - Key offerings
              • Exhibit 158: Otsuka Holdings Co. Ltd. - Segment focus
            • 12.13 Pfizer Inc.
              • Exhibit 159: Pfizer Inc. - Overview
              • Exhibit 160: Pfizer Inc. - Product / Service
              • Exhibit 161: Pfizer Inc. - Key news
              • Exhibit 162: Pfizer Inc. - Key offerings
            • 12.14 Sanofi SA
              • Exhibit 163: Sanofi SA - Overview
              • Exhibit 164: Sanofi SA - Business segments
              • Exhibit 165: Sanofi SA - Key news
              • Exhibit 166: Sanofi SA - Key offerings
              • Exhibit 167: Sanofi SA - Segment focus
            • 12.15 TerSera Therapeutics LLC
              • Exhibit 168: TerSera Therapeutics LLC - Overview
              • Exhibit 169: TerSera Therapeutics LLC - Product / Service
              • Exhibit 170: TerSera Therapeutics LLC - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 171: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 176: Viatris Inc. - Overview
              • Exhibit 177: Viatris Inc. - Business segments
              • Exhibit 178: Viatris Inc. - Key news
              • Exhibit 179: Viatris Inc. - Key offerings
              • Exhibit 180: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 181: Inclusions checklist
                • Exhibit 182: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 183: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 184: Research methodology
                • Exhibit 185: Validation techniques employed for market sizing
                • Exhibit 186: Information sources
              • 13.5 List of abbreviations
                • Exhibit 187: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              urticaria drugs market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis